(Q43673455)

25 November 2017

title

Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours (English)

1 reference

25 November 2017

1 reference

1 reference

1 reference

Moodley D

1

1 reference

25 November 2017

Pillay K

2

1 reference

25 November 2017

Naidoo K

3

1 reference

25 November 2017

Moodley J

4

1 reference

25 November 2017

Johnson MA

5

1 reference

25 November 2017

Moore KH

6

1 reference

25 November 2017

Mudd PN Jr

7

1 reference

25 November 2017

Pakes GE

8

1 reference

25 November 2017

publication date

1 July 2001

1 reference

The Journal of Clinical Pharmacology

25 November 2017

published in

1 reference

25 November 2017

volume

41

1 reference

25 November 2017

issue

7

1 reference

25 November 2017

page(s)

732-741

1 reference

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. Women and Infants Tran

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Acceptability and impact of zidovudine for prevention of mother-to-child human immunodeficiency virus-1 transmission in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African Developing country setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Antiretroviral drugs as a public health intervention for pregnant HIV-infected women in rural South Africa: an issue of cost-effectiveness and capacity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Cost-effectiveness and cost-benefit in the prevention of mother-to-child transmission of HIV in developing countries. Ghent International Working Group on Mother-to-Child Transmission of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Clinical pharmacokinetics of lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Placental transfer of drugs administered to the mother

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Pharmacokinetics of anti-infective agents in paediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

The transfer of anti-human immunodeficiency virus nucleoside compounds by the term human placenta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

High-performance liquid chromatographic assay for 2'-deoxy-3'-thiacytidine in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Transfer of zidovudine (AZT) by human placenta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

The maternal-fetal transfer of lamivudine in the ex vivo human placenta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

10.1177/00912700122010636

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference